Filing Details

Accession Number:
0001179110-20-010699
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-10-28 18:33:28
Reporting Period:
2020-10-26
Accepted Time:
2020-10-28 18:33:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1800 Abbott Laboratories ABT Pharmaceutical Preparations (2834) 360698440
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1565892 E Robert Funck 100 Abbott Park Road
Abbott Park IL 60064-6400
Executive Vice President & Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Without Par Value Acquisiton 2020-10-26 83,333 $38.40 265,550 No 4 M Direct
Common Shares Without Par Value Disposition 2020-10-26 83,333 $108.83 182,217 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Shares Option (right to buy) Disposition 2020-10-26 83,333 $0.00 83,333 $38.40
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2019-02-19 2026-02-18 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Shares Without Par Value 17,702 Indirect Profit Sharing Trust
Common Shares Without Par Value 500 Indirect By Daughter
Common Shares Without Par Value 500 Indirect By Daughter
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.75 to $108.93, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  2. Balance in the Abbott Laboratories Stock Retirement Trust as of October 26, 2020.
  3. The reporting person disclaims beneficial ownership of all securities held by his daughter.
  4. Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.